Who gets antidotes? choosing the chosen few.

作者: Nicholas A. Buckley , Andrew H. Dawson , David N. Juurlink , Geoffrey K. Isbister

DOI: 10.1111/BCP.12894

关键词:

摘要: An understanding of mechanisms, potential benefits and risks antidotes is essential for clinicians who manage poisoned patients. Of the dozens currently available, only a few are regularly used. These include activated charcoal, acetylcysteine, naloxone, sodium bicarbonate, atropine, flumazenil, therapeutic antibodies various vitamins. Even then, most used in minority poisonings. There little randomized trial evidence to support use antidotes. Consequently, decisions about when them often based on mechanistic poisoning expected influence antidote patient's clinical course. For some antidotes, such as atropine insulin, doses employed can be orders magnitude higher than standard dosing. Importantly, patients reach hospital recover with supportive care alone. In low risk patients, routine even charcoal unwarranted. more serious poisonings, regarding generally guided by risk/benefit assessment quality evidence.

参考文章(29)
Darren M. Roberts, Gamini Gallapatthy, Asunga Dunuwille, Betty S. Chan, Pharmacological treatment of cardiac glycoside poisoning. British Journal of Clinical Pharmacology. ,vol. 81, pp. 488- 495 ,(2016) , 10.1111/BCP.12814
Michael Eddleston, Fazle Rabbi Chowdhury, Pharmacological treatment of organophosphorus insecticide poisoning: the old and the (possible) new. British Journal of Clinical Pharmacology. ,vol. 81, pp. 462- 470 ,(2016) , 10.1111/BCP.12784
D. Nicholas Bateman, Colin B. Page, Antidotes to coumarins, isoniazid, methotrexate and thyroxine, toxins that work via metabolic processes British Journal of Clinical Pharmacology. ,vol. 81, pp. 437- 445 ,(2016) , 10.1111/BCP.12736
Hsien-Yi Chen, Timothy E. Albertson, Kent R. Olson, Treatment of drug‐induced seizures British Journal of Clinical Pharmacology. ,vol. 81, pp. 412- 419 ,(2016) , 10.1111/BCP.12720
Marco L.A. Sivilotti, Flumazenil, naloxone and the ‘coma cocktail’ British Journal of Clinical Pharmacology. ,vol. 81, pp. 428- 436 ,(2016) , 10.1111/BCP.12731
Angela L. Chiew, Geoffrey K. Isbister, Stephen B. Duffull, Nicholas A. Buckley, Evidence for the changing regimens of acetylcysteine British Journal of Clinical Pharmacology. ,vol. 81, pp. 471- 481 ,(2016) , 10.1111/BCP.12789
H. Asita de Silva, Nicole M. Ryan, H. Janaka de Silva, Adverse reactions to snake antivenom, and their prevention and treatment British Journal of Clinical Pharmacology. ,vol. 81, pp. 446- 452 ,(2016) , 10.1111/BCP.12739
H. Asita de Silva, Arunasalam Pathmeswaran, Channa D. Ranasinha, Shaluka Jayamanne, Senarath B. Samarakoon, Ariyasena Hittharage, Ranjith Kalupahana, G. Asoka Ratnatilaka, Wimalasiri Uluwatthage, Jeffrey K. Aronson, Jane M. Armitage, David G. Lalloo, H. Janaka de Silva, Low-Dose Adrenaline, Promethazine, and Hydrocortisone in the Prevention of Acute Adverse Reactions to Antivenom following Snakebite: A Randomised, Double-Blind, Placebo-Controlled Trial PLOS Medicine. ,vol. 8, ,(2011) , 10.1371/JOURNAL.PMED.1000435
Geoffrey K Isbister, Colin B Page, Nicholas A Buckley, Daniel M Fatovich, Ovidiu Pascu, Stephen PJ MacDonald, Leonie A Calver, Simon GA Brown, RAVE Investigators, None, Randomized controlled trial of intravenous antivenom versus placebo for latrodectism: the second Redback Antivenom Evaluation (RAVE-II) study. Annals of Emergency Medicine. ,vol. 64, pp. 620- 628 ,(2014) , 10.1016/J.ANNEMERGMED.2014.06.006
E.A. Sandilands, D.N. Bateman, Adverse reactions associated with acetylcysteine. Clinical Toxicology. ,vol. 47, pp. 81- 88 ,(2009) , 10.1080/15563650802665587